Targeted therapies tailored to disease biology.
Our precision medicine approach pairs deep immunological insights with human genetics, helping to define immune-mediated diseases (IMDs) by their molecular and cellular signatures.
Understanding the causal cellular drivers of disease allows us to rapidly advance programs from early discovery through clinical development, with a focus on reaching patients that are most likely to benefit from our novel therapeutic agents.
Many IMDs stem from the dysfunction of cells that make up the immune system. Our initial therapeutic programs target, modulate or deplete these cellular drivers of disease. Different IMDs often share the same cellular drivers of disease, and we aim to expand each of our programs to multiple other indications in the IMD landscape.
At HI-Bio, we are bringing a fresh perspective to develop treatments for IMDs through our clinical-stage programs and pipeline.
FelzartamabPrimary Membranous Nephropathy
Felzartamab is an antibody directed against CD38, a protein expressed on the surface of mature plasma cells. When applied, felzartamab is believed to deplete plasma cells, which are believed to drive certain diseases, such as Primary Membranous Nephropathy, through their production of autoantibodies.
HI-Bio holds executive worldwide rights for felzartamab with the exception of Greater China.
IgA Nephropathy
Felzartamab is an antibody directed against CD38, a protein expressed on the surface of mature plasma cells. When applied, felzartamab is believed to deplete plasma cells, which are believed to drive certain diseases, such as IgA Nephropathy, through their production of autoantibodies.
HI-Bio holds executive worldwide rights for felzartamab with the exception of Greater China.
Antibody Mediated Transplant Rejection
Felzartamab is an antibody directed against CD38, a protein expressed on the surface of mature plasma cells. When applied, felzartamab is believed to deplete plasma cells, which are believed to drive certain diseases, such as Antibody Mediated Transplant Rejection, through their production of autoantibodies.
HI-Bio holds executive worldwide rights for felzartamab with the exception of Greater China.
HIB210Undisclosed
HIB210 is an anti-C5aR1 antibody with the potential to be a best-in-class therapy for complement-mediated diseases including ANCA Associated Vasculitis (AAV), Hidradenitis Suppurativa, C3 Glomerulonephropathy and Lupus Nephritis. When compared to existing agents, it has shown greater activity against neutrophils, a cell type key to driving several IMDs.
HI-Bio holds exclusive worldwide rights for HIB210 with the exception of Greater China and South Korea for HIB210.
Mast Cell ProgramUndisclosed
We are advancing discovery programs targeted at dysfunction of mast cells implicated in several indications.
Our precision immunology toolkit helps translate insights that emerge from our ongoing research and development efforts. Through efforts to profile the immune phenotypes that drive IMDs, HI-Bio’s translational toolkit has the potential to address multiple diseases with high unmet medical needs throughout the IMD landscape.
The four pillars of the HI-Bio toolkit:
Identifying and validating targets, discovering causal biomarkers and optimizing patient selection
Assessing the role of select targets and establishing biomarker strategies to increase confidence in our therapeutics and define patient subsets for any given indication